胶质瘤的治疗管理仍然极具挑战性。脑肿瘤呈现多重障碍，使得治疗创新变得复杂，主要原因是血液肿瘤和血脑屏障（BTB和BBB，分别）的存在，阻止抗癌药物进入脑实质。通过聚焦超声介导的BBB破坏（FUS-BBBD），提供了一种非侵入性、局部和可逆的BBB破坏的物理方法。这种技术的安全性已在小型和大型动物模型中得到证明。该方法承诺通过重新利用现有药物，增强药物输送到脑肿瘤中，从而改善生存结果。在过去的十年中，已经启动了几个临床试验。在本综述中，我们概述了FUS-BBBD在胶质瘤中使用的理论基础，并总结了研究不同方法（游离药物、载药微泡和载药纳米载体）与该技术结合在体内胶质瘤模型中的预临床研究。此外，我们讨论了目前的临床试验和开发的设备，并回顾了克服FUS-BBBD在胶质瘤治疗中的临床使用的挑战。版权所有 © 2023. 由Elsevier Inc.出版。

The therapeutic management of gliomas remains particularly challenging. Brain tumors present multiple obstacles that make therapeutic innovation complex, mainly due to the presence of blood-tumor and blood-brain barriers (BTB and BBB, respectively) which prevent penetration of anticancer agents into the brain parenchyma. Focused ultrasound-mediated BBB disruption (FUS-BBBD) provides a physical methosd for non-invasive, local, and reversible BBB disruption. The safety of this technique has been demonstrated in small and large animal models. This approach promises to enhance drug delivery into the brain tumor and therefore to improve survival outcomes by repurposing existing drugs. Several clinical trials continue to be initiated in the last decade. In this review, we provide an overview of the rationale behind the use of FUS-BBBD in gliomas and summarize the preclinical studies investigating different approaches (free drugs, drug-loaded microbubbles and drug-loaded nanocarriers) in combination with this technology in in vivo glioma models. Furthermore, we discuss the current state of clinical trials and devices developed and review the challenges to overcome for clinical use of FUS-BBBD in glioma therapy.Copyright © 2023. Published by Elsevier Inc.